Fulgent Genetics, Inc. FLGT Laboratory Services — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Fulgent Genetics, Inc.'s laboratory services — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Fulgent Genetics, Inc.'s laboratory services — research and development expense?
- Fulgent Genetics, Inc. (FLGT) reported laboratory services — research and development expense of $6.46M in Q1 2026.
- How has Fulgent Genetics, Inc.'s laboratory services — research and development expense changed year-over-year?
- Fulgent Genetics, Inc.'s laboratory services — research and development expense increased by 31.0% year-over-year, from $4.93M to $6.46M.
- What is the long-term trend for Fulgent Genetics, Inc.'s laboratory services — research and development expense?
- Over 3 years (2022 to 2025), Fulgent Genetics, Inc.'s laboratory services — research and development expense has grown at a 6.9% compound annual growth rate (CAGR), from $17.72M to $21.64M.
- What does laboratory services — research and development expense mean?
- These are the costs incurred to develop new diagnostic tests, improve existing laboratory methodologies, and advance genetic testing technologies. This investment reflects the company's commitment to maintaining a competitive edge through innovation in the clinical diagnostics market.